B002
/ Shanghai Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 24, 2023
B002-101: B002 in Patients With HER2-positive Breast Cancer
(clinicaltrials.gov)
- P1 | N=23 | Completed | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Apr 2022 | Trial primary completion date: Feb 2023 ➔ Apr 2022
Metastases • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor
October 21, 2022
B002-101: B002 in Patients With HER2-positive Breast Cancer
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Dec 2022
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor
August 01, 2022
B002-101: B002 in Patients With HER2-positive Breast Cancer
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Mar 2021 ➔ Dec 2022 | Trial primary completion date: Sep 2020 ➔ Sep 2022
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor
July 10, 2020
B002-101: B002 in Patients With HER2-positive Breast Cancer
(clinicaltrials.gov)
- P1; N=19; Recruiting; Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd; Trial primary completion date: May 2020 ➔ Sep 2020
Clinical • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1